Estrogen and Progesterone Receptor Assay in Paraffin-Embedded Breast Cancer

Chebil, Gunilla; Bendahl, Pär‐Ola; Fernö, Mårten

doi:10.1080/02841860300672

Cited by 22 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, one report stated that the use of immunohistochemistry to determine ER was superior to that of biochemical assays for predicting response to therapy (336 ). Compared to ER, fewer data are available on the clinical value of PR as determined by immunohistochemistry (341)(342)(343). As with ER, the predictive power of PR as determined by immunohistochemistry appears to be superior to that obtained using ligand-binding assays (343 ).…”

Section: Recommendationsmentioning

confidence: 99%

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

et al. 2008

View full text Add to dashboard Cite

Background: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. Methods: Published reports relevant to use of tumor markers for 5 cancer sites—testicular, prostate, colorectal, breast, and ovarian—were critically reviewed. Results: For testicular cancer, α-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. α-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors. Prostate-specific antigen (PSA) is not recommended for prostate cancer screening, but may be used for detecting disease recurrence and monitoring therapy. Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is <10 μg/L. In colorectal cancer, carcinoembryonic antigen is recommended (with some caveats) for prognosis determination, postoperative surveillance, and therapy monitoring in advanced disease. Fecal occult blood testing may be used for screening asymptomatic adults 50 years or older. For breast cancer, estrogen and progesterone receptors are mandatory for predicting response to hormone therapy, human epidermal growth factor receptor-2 measurement is mandatory for predicting response to trastuzumab, and urokinase plasminogen activator/plasminogen activator inhibitor 1 may be used for determining prognosis in lymph node–negative patients. CA15-3/BR27–29 or carcinoembryonic antigen may be used for therapy monitoring in advanced disease. CA125 is recommended (with transvaginal ultrasound) for early detection of ovarian cancer in women at high risk for this disease. CA125 is also recommended for differential diagnosis of suspicious pelvic masses in postmenopausal women, as well as for detection of recurrence, monitoring of therapy, and determination of prognosis in women with ovarian cancer. Conclusions: Implementation of these recommendations should encourage optimal use of tumor markers.

show abstract

Section: Recommendationsmentioning

confidence: 99%

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

et al. 2008

View full text Add to dashboard Cite

show abstract

“…The patients in Helsingborg are somewhat older and different sets of antibodies are used at different Departments of pathology. ER and PR status was independently re-assessed by 22 pathologists from nine hospitals and the kappa values were 0.78 for ER and 0.72 for PR in 2003 (Chebil et al, 2003). Provided that these markers are used for selection of breast cancer treatment, quality assurance is ongoing.…”

Section: Discussionmentioning

confidence: 99%

CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients

et al. 2009

View full text Add to dashboard Cite

BACKGROUND: CYP2C8/9 polymorphisms may influence breast cancer-free survival after diagnosis due to their role in the metabolism of tamoxifen, paclitaxel, and other chemotherapy. cytochrome P450 (CYP)2C8/9 metabolise arachidonic acid to epoxyeicosatrienoic acids, which enhance migration and invasion in vitro and promote angiogenesis in vivo. We aimed to investigate the frequency of CYP2C8/9 polymorphisms in relation to breast tumour characteristics and disease-free survival. METHODS: A prospective series of 652 breast cancer patients from southern Sweden was genotyped for CYP2C8*3, CYP2C8*4, CYP2C9*2, and CYP2C9*3. Blood samples and questionnaires were obtained pre-and postoperatively. Clinical information and tumour characteristics were obtained from patients' charts and pathology reports. RESULTS: Frequencies of CYP2C8/9 polymorphisms were similar to healthy European populations. Significantly less node involvement (P ¼ 0.002) and fewer PR þ tumours (P ¼ 0.012) were associated with CYP2C8*4. Median follow-up was 25 months and 52 breast cancer-related events were reported. In a multivariate model, CYP2C8/9*3/*1*/*2/*1 was the only factor associated with increased risk for early events in 297 tamoxifen-treated, ER-positive patients, adjusted HR 2.54 (95%CI 1.11 -5.79). The effect appeared to be driven by CYP2C8*3, adjusted HR 8.56 (95%CI 1.53 -51.1). CONCLUSION: Polymorphic variants of CYP2C8/9 may influence breast tumour characteristics and disease-free survival in tamoxifentreated patients.

show abstract

“…Studies that document interobserver variability in binary (positive or negative) hormone receptor assessment have generally observed that ER and PR concordance was "good" (κ values for interobserver agreement ranging from 0.57 to 0.87) [13,[15][16][17]19]. However, few have evaluated interobserver agreement using semiquantitative methods, with Cohen et al 2012 serving as a notable exception [20].…”

Section: Discussionmentioning

confidence: 94%

“…The University of California Athena Breast Health Network has demonstrated that variation between expert observers exists and that technical and interpretive harmonization between expert observers is possible [11,12]. Previous reports of measuring and improving interobserver variability in breast biomarker scoring are limited [13][14][15][16][17]. A minority used semiquantitative scoring methods, and no studies to date have attempted to document improvement through training.…”

Section: Introductionmentioning

confidence: 99%

“Score the Core” Web-based pathologist training tool improves the accuracy of breast cancer IHC4 scoring

et al. 2015

View full text Add to dashboard Cite

Estrogen and Progesterone Receptor Assay in Paraffin-Embedded Breast Cancer

Cited by 22 publications

References 17 publications

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients

“Score the Core” Web-based pathologist training tool improves the accuracy of breast cancer IHC4 scoring

Contact Info

Product

Resources

About